Tag Archives: Health Technology
PBAC Meeting Agenda – July 2018
The July 2018 PBAC Meeting is scheduled from 4 to 6 Jul 2018. Here, the Commercial Eyes Market Access team provides an overview of the meeting agenda, including submissions relating to biosimilars lodged for this meeting. The Commercial … Continue reading
What is food for special medical purposes (FSMP)?
With a greater recognition of the importance of nutritional support in medical therapy and improved technology, the “food for special medical purposes” (FSMP) market is currently surging. However, many questions arise, what is food for special medical purposes? Where can … Continue reading
Multi-criteria decision making – How can non-health attributes be considered and valued?
Pressure is mounting on decisions to recommend and continue funding health technologies. Concerns around the rising cost of new medicines, an ageing population with greater resource utilisation, federal and state healthcare budgetary constraints, and an increasing dependency ratio (the ratio … Continue reading
Successful innovation has economic and social benefits such as creating jobs and improving the quality of lives
With the launch of Malcolm Turnbull’s Innovation statement and Innovation Week 2015 in Victoria last week, the hot topic of discussion is ‘innovation’. Here’s what Andrew Carter, Commercial Eyes Managing Director and Chair of BioMelbourne Network, has to say… Policies that … Continue reading
Medical Information by instant message
1800 numbers and written responses such as letters and emails are a well-established part of all Medical Information services. However consumers and healthcare professionals are increasingly tech-savvy. They may prefer to communicate via text or online chat as they do … Continue reading
NZ Regs Shake-up – what will become of medical devices?
The New Zealand Ministry of Health has announced that they are developing a new regime for the regulation of therapeutic products. Following the cessation of the Australia New Zealand Therapeutic Products Agency (ANZTPA), the New Zealand Ministry of Health is … Continue reading
Launch sequencing and the 5% F1 price cut: strategic considerations for your patented medicine
Achieving optimal prices for patented medicines is a critical issue close to the heart of the pharmaceutical industry. The 2015/16 Federal Budget introduced new savings measures with implications for prices of patented medicines in Australia. In the current environment, launch … Continue reading
Funding pathways for new technologies
Recently, the topic of funding pathways for new technologies was discussed as part of a speaker session at the 2015 ARCS Scientific Congress, at Royal Randwick Sydney. Professor Robyn Ward, the current Chairperson of MSAC and a member of the … Continue reading
2014 ARCS scientific congress: ethics in HTA and decision-making
clinical trial design – overcoming the odds
Drug development costs anywhere between $1-4 billion by the time costs of failed drug candidates are factored in. A new drug can take anywhere from 10-15 years to obtain approval for human use. 80-85% of compounds fail early phase clinical … Continue reading
